A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Participants with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Rocky Mountain Regional VA Medical Center

Principal Investigator
Photograph of Daniel Bowles,  MD

Daniel Bowles, MD

Study ID

Protocol Number: 20-2644

More information available at ClinicalTrials.gov: NCT04590963

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers